MyChesCo on MSN1mon
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic ShockWARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, ...
MyChesCo on MSN4mon
Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updateswe plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study as well as provide guidance on our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback